Gregory M. Weinhoff, M.D.

Greg is a graduate of Harvard College, Harvard Medical School and Harvard Business School, where he was a Baker Scholar.

Prior to joining CHL Medical Partners in 2001, Greg was a Senior Associate at Whitney & Co. where he concentrated on private equity investments in healthcare technology and services companies. Prior to his graduate training, Greg was a financial analyst in the Healthcare Corporate Finance Group at Morgan Stanley & Co. where he worked on financings and merger and acquisition assignments for a number of biotechnology, pharmaceutical, and healthcare services clients.

While at CHL, Greg has been the founding CEO of Amicus Therapeutics, Inc. where he has played a key role in identifying and licensing the platform technology, hiring the management team and developing the company's strategic plan. He also played a key role in the early development and financing of Fidelis SeniorCare, Inc., iVital, Inc., Resolvyx Pharmaceuticals, Inc. and VaxInnate Corporation. He currently serves as a director of these five companies.

Greg can be reached at gweinhoff@chlmedical.com.